In a study conducted by Li et al.,34 the aim was to assess the prognostic and therapeutic role of lncRNA MALAT1 in CRC patients receiving oxaliplatin‐based treatment, as well as its possible transcriptional regulation through interaction with EZH2 in oxaliplatin‐resistant CRC cells. This evidence concerns the gene EZH2 and colorectal carcinoma.